Theratechnologies Expands Peptide Portfolio in Endocrinology with the Addition of a GLP-1 Program for the Treatment of Type II Diabetes (PR Newswire)

Actinium Pharmaceuticals Announces Collaboration with Memorial Sloan Kettering Cancer Center for a Novel Targeted Cancer Immunotherapy (PR Newswire)
..."API brings its supporting patent position for use of these unique, short half-life alpha-particle emitting radioisot...

MGI PHARMA & HELSINN Submit NDA for Palonosetron (Business Wire)
... selective 5-HT3 receptor antagonist with a strong receptor-binding affinity and an extended plasma half-life, in dev...

Theratechnologies Expands Peptide Portfolio in Endocrinology with the Addition of a GLP-1 Program for the Treatment of Type II Diabetes (Canada NewsWire)
... hydrophobic chain to peptides in order to slow their enzymatic degradation and increase their half-life.......

Enzon Reports Schering-Plough Announces Launch of PEG-INTRON Pre-Filled Pen in Europe (Business Wire)
... once-weekly therapy designed to optimize the balance between antiviral activity and elimination half-life.......

BioSyntech Inc.: A Novel Non-Toxic Sustained Release Taxol Formulation for Cancer Chemotherapy (CCNMatthews)
...It is understandable based on the half life (t1/2) of about 6 hours for the free Taxol.......

BioSyntech Inc.: A Novel Non-Toxic Sustained Release Taxol Formulation for Cancer Chemotherapy (Business Wire)
...It is understandable based on the half life (t1/2) of about 6 hours for the free Taxol.......